Compare Adaptive Biotechnologies Corp (ADPT) vs Solaredge Technologies Inc (SEDG) Price & Performance

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

SolarEdge Technologies (SEDG) trades at $32.04, down 0.53% on the day, reflecting ongoing volatility amid mixed financial performance. The stock exhibits a bearish technical trend, with negative profitability metrics including a net income margin of -20.29% and ROE of -58.42% for 2026. Recent Q2 2026 earnings beat expectations with EPS of $0.06, but weak Q3 revenue guidance has pressured shares. Cash flow improved in 2025 with net cash flow of $138.60 million, though debt levels remain elevated.

The outlook is cautious due to persistent losses, high dependence on policy incentives, and a challenging U.S. residential solar market. Analyst consensus is mixed with a hold-heavy rating (58.34%) and a $35.15 price target, suggesting limited near-term upside. Key risks include execution missteps, competitive pressures, and macroeconomic headwinds, requiring careful monitoring of margin recovery and demand trends.